tradingkey.logo

Rocket Pharmaceuticals Provides Update On Phase 2 Clinical Trial Of Rp-A501 For Danon Disease

ReutersMay 27, 2025 12:10 PM

- Rocket Pharmaceuticals Inc RCKT.O:

  • ROCKET PHARMACEUTICALS PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF RP-A501 FOR DANON DISEASE

  • ROCKET PHARMACEUTICALS INC - IN ACTIVE DIALOGUE WITH FDA AFTER SAE IN RP-A501 TRIAL

  • ROCKET PHARMACEUTICALS INC - FDA PLACES CLINICAL HOLD ON RP-A501 TRIAL AFTER SAE

  • ROCKET PHARMACEUTICALS INC - PATIENT IN RP-A501 PHASE 2 TRIAL EXPERIENCES SERIOUS ADVERSE EVENT

  • ROCKET PHARMACEUTICALS INC - EXPECTS RESOURCES TO FUND OPERATIONS INTO 2027

  • ROCKET PHARMACEUTICALS INC - UNABLE TO PROVIDE GUIDANCE ON ANTICIPATED TIMING FOR COMPLETION OF PHASE 2 TRIAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI